Colorectal cancer (CRC) stands as a global health challenge, ranking as the third most prevalent cancer and claiming over 500,000 lives annually. Despite advancements in treatment modalities like surgery, chemotherapy, radiotherapy, and targeted therapies such as anti-VEGF and anti-EGFR, the 5-year survival rate for metastatic CRC hovers around 35-40%, underscoring the pressing need for further insights. Metastasis, particularly hepatic metastasis affecting half of CRC patients, significantly impacts survival rates, emphasizing the urgency of unraveling molecular mechanisms governing proliferation, migration, and invasion.
The intricate landscape of CRC involves a complex interplay of genetic and epigenetic factors, encompassing genetic mutations (APC, KRAS, TP53), DNA methylation, histone modifications, and non-coding RNA. Understanding these mechanisms is vital for refining diagnostic and therapeutic strategies. Exploration of epigenetic changes and their impact on gene expression offers potential avenues for targeted interventions.
MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) emerge as crucial players in CRC progression. Genetic predispositions, exemplified by Lynch syndrome and APC gene mutations, underscore the hereditary facet of CRC.
Unraveling the molecular intricacies of CRC not only sheds light on its etiology but also paves the way for innovative therapeutic approaches, offering hope for improved outcomes in the face of this formidable disease.
Understanding the molecular mechanisms and therapies for colorectal cancer remains complex. This Research aims to provide insight into the research around understanding molecular mechanisms and targeted therapies that impact colorectal cancer. Topics of interest include:
-Role of micro-RNAs (miRNAs) in the progression of colorectal cancer
-Epigenetic modifications in CRC development include DNA methylation, histone modifications, and non-coding RNA involvement.
-Biomarkers as potential diagnostic markers
-Influence of genetic variations and mutations on CRC
-Novel therapies to help CRC patient survival and prognosis
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Colorectal cancer (CRC) stands as a global health challenge, ranking as the third most prevalent cancer and claiming over 500,000 lives annually. Despite advancements in treatment modalities like surgery, chemotherapy, radiotherapy, and targeted therapies such as anti-VEGF and anti-EGFR, the 5-year survival rate for metastatic CRC hovers around 35-40%, underscoring the pressing need for further insights. Metastasis, particularly hepatic metastasis affecting half of CRC patients, significantly impacts survival rates, emphasizing the urgency of unraveling molecular mechanisms governing proliferation, migration, and invasion.
The intricate landscape of CRC involves a complex interplay of genetic and epigenetic factors, encompassing genetic mutations (APC, KRAS, TP53), DNA methylation, histone modifications, and non-coding RNA. Understanding these mechanisms is vital for refining diagnostic and therapeutic strategies. Exploration of epigenetic changes and their impact on gene expression offers potential avenues for targeted interventions.
MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) emerge as crucial players in CRC progression. Genetic predispositions, exemplified by Lynch syndrome and APC gene mutations, underscore the hereditary facet of CRC.
Unraveling the molecular intricacies of CRC not only sheds light on its etiology but also paves the way for innovative therapeutic approaches, offering hope for improved outcomes in the face of this formidable disease.
Understanding the molecular mechanisms and therapies for colorectal cancer remains complex. This Research aims to provide insight into the research around understanding molecular mechanisms and targeted therapies that impact colorectal cancer. Topics of interest include:
-Role of micro-RNAs (miRNAs) in the progression of colorectal cancer
-Epigenetic modifications in CRC development include DNA methylation, histone modifications, and non-coding RNA involvement.
-Biomarkers as potential diagnostic markers
-Influence of genetic variations and mutations on CRC
-Novel therapies to help CRC patient survival and prognosis
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
